Scientists 'tinker' with HIV drug chemistry hoping to reduce costs

NewsGuard 100/100 Score

The Clinton Health Access Initiative, founded by former President Bill Clinton, with funding from the Bill & Melinda Gates Foundation and the U.K. government, has hired former pharmaceutical company scientists "to tinker with the chemistry used to synthesize a key [HIV] drug, tenofovir" in an effort to reduce "the cost of manufacturing," the Wall Street Journal reports.

"The chemistry effort represents a new sophistication among AIDS advocates, who fear a wave of HIV deaths in developing countries due to flat funding for international treatment programs," the newspaper writes. The Clinton team is also looking at how to make antiretroviral drugs that are more easily absorbed by the body, which "would allow each pill to contain less antiretroviral medication while achieving the same effects," according to the Wall Street Journal (Schoofs, 5/13).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    1. HLovingCom HLovingCom United States says:

      It would be good if the antiretroviral drugs could make a difference.

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    Research validates concurrent use of HIV medications and gender-affirming hormone therapy